L
Larimar Therapeutics, Inc. (LRMR)
NGM – Real Time Price. Currency in USD
4.13
+0.04 (0.98%)
At close: May 12, 2026, 4:00 PM EDT
4.13
0.00 (0.00%)
After-hours: May 12, 2026, 6:20 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NGM – Real Time Price. Currency in USD
4.13
+0.04 (0.98%)
At close: May 12, 2026, 4:00 PM EDT
4.13
0.00 (0.00%)
After-hours: May 12, 2026, 6:20 PM EDT
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich’s ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania.
| Name | Position |
|---|---|
| Dr. Carole S. Ben-Maimon M.D. | CEO, President & Director |
| Dr. Gopi Shankar M.B.A., Ph.D. | Chief Development Officer |
| Dr. Russell G. Clayton Sr., D.O. | Chief Medical Officer |
| Mr. Francis Michael Conway CPA | VP & Controller |
| Mr. John Berman | Vice President of Finance & Administration |
| Mr. Michael Celano CPA | Secretary & CFO |
| Date | Type | Document |
|---|---|---|
| 2026-04-20 | DEF 14A | lrmr-20260416.htm |
| 2026-04-10 | PRE 14A | lrmr-20260410.htm |
| 2026-03-19 | S-8 | d122362ds8.htm |
| 2026-03-19 | 10-K | lrmr-20251231.htm |
| 2026-03-09 | 8-K | lrmr-20260309.htm |
| 2026-02-27 | 8-K | d120172d8k.htm |
| 2026-02-24 | 8-K | lrmr-20260224.htm |
| 2026-01-22 | 8-K | d27699d8k.htm |
| 2026-01-12 | 8-K | lrmr-20260112.htm |
| 2025-12-17 | 8-K | d42051d8k.htm |
| Ms. Jennifer Spokes Johansson | Vice President of Legal & Compliance |